HCGvsHMG

Human Chorionic Gonadotropin is a glycoprotein hormone composed of two non-covalently linked subunits: an alpha subunit (92 amino acids, shared with LH, FSH, and TSH) and a unique beta subunit (145 amino acids) that confers biological specificity. HCG's beta subunit shares approximately 85% amino acid homology with the LH beta subunit, allowing HCG to bind and activate the LH/CG receptor (LHCGR) on Leydig cells in the testes with equal or greater affinity than LH itself.

LHCGR is a Gs-coupled GPCR that activates adenylyl cyclase upon ligand binding, increasing intracellular cAMP. cAMP activates PKA, which phosphorylates the steroidogenic acute regulatory protein (StAR). Phosphorylated StAR transports cholesterol from the outer to the inner mitochondrial membrane — the rate-limiting step in steroid hormone synthesis. Inside the mitochondria, the cholesterol side-chain cleavage enzyme (CYP11A1) converts cholesterol to pregnenolone, which then undergoes a series of enzymatic conversions (through the delta-4 or delta-5 pathway) to produce testosterone. This entire steroidogenic cascade occurs within Leydig cells and produces intratesticular testosterone concentrations 50-100 times higher than serum levels — essential for spermatogenesis in the adjacent seminiferous tubules.

HCG's longer half-life compared to LH (24-36 hours vs 20 minutes) is due to its heavily glycosylated beta subunit, which reduces renal clearance. This extended duration makes it practical for intermittent injection protocols. In addition to stimulating testosterone, HCG activates aromatase (CYP19A1) in Leydig cells, converting some of the produced testosterone to estradiol — which is why HCG use can elevate estrogen levels, potentially causing gynecomastia and water retention. HCG also maintains Sertoli cell function (which supports spermatogenesis) through indirect paracrine signaling from testosterone-producing Leydig cells. The physical preservation of testicular volume during TRT is a direct result of maintained Leydig cell activity and seminiferous tubule function.

Human Menopausal Gonadotropin is a purified urinary extract containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, sourced from the urine of postmenopausal women. After menopause, the loss of ovarian negative feedback (estradiol and inhibin) results in dramatically elevated pituitary gonadotropin secretion — FSH and LH levels rise 10-20 fold, providing a natural source of these hormones for pharmaceutical extraction.

The FSH component binds to FSH receptors (FSHR) on Sertoli cells in males and granulosa cells in females. FSHR is a Gs-coupled GPCR that activates cAMP/PKA signaling, driving the expression of genes essential for gametogenesis. In males, FSH-stimulated Sertoli cells produce androgen-binding protein (which concentrates testosterone locally), inhibin B (which provides negative feedback to the pituitary), and multiple growth factors that support spermatogonial proliferation and differentiation through the stages of spermatogenesis. In females, FSH drives follicular development — stimulating granulosa cell proliferation, estradiol synthesis via aromatase induction, and the growth of ovarian follicles from the pre-antral to the pre-ovulatory stage.

The LH component acts on Leydig cells in males (stimulating testosterone production via the LHCGR/cAMP/StAR steroidogenic pathway) and on theca cells in females (stimulating androgen precursor production that granulosa cells convert to estradiol). In females undergoing fertility treatment, the LH component is also critical for final oocyte maturation and ovulation triggering. The combination of both FSH and LH activity in HMG provides more complete gonadal stimulation than either gonadotropin alone — FSH drives the cellular proliferation and maturation processes while LH provides the steroidogenic and final maturation signals. This dual activity is why HMG is sometimes preferred over purified FSH preparations in certain fertility protocols, particularly in hypogonadotropic patients who lack endogenous LH.